Chimie physique générale, Biochimie, Biologie moléculaire ,
Chimie thérapeutique, Chimie thérapeutique François BONNEAUX ,
Hématologie -Génie Biologique, Chimie thérapeutique François DUPUIS..............................................Pharmacologie Raphaël DUVAL ..............................................Microbiologie clinique ,
Biophysique ,
Pharmacie galénique ASSISTANTS HOSPITALO-UNIVERSITAIRES, Biochimie et Biologie ,
41 2.1.4.3. Préparation des échantillons de sang 42 2.1.5. Validation de la méthode selon les normes COFRAC ,
69 4.1.1. Aspects techniques, Conclusion et perspectives, p.72 ,
Chronic Myeloid Leukemia ??? Advances in Biology and New Approaches to Treatment, New England Journal of Medicine, vol.349, issue.15, pp.1451-64, 2003. ,
DOI : 10.1056/NEJMra020777
Atomic bomb and leukemia, J ,
Chromosome studies on normal and leukemic human leukocytes, J Natl Cancer Inst, vol.25, pp.85-109, 1960. ,
A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining, Nature, vol.71, issue.5405, pp.290-293, 1973. ,
DOI : 10.7326/0003-4819-72-2-175
Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia ,
Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders, European Journal of Clinical Pharmacology, vol.101, issue.6, pp.545-554, 2009. ,
DOI : 10.1007/s00228-009-0621-z
Relationship of serum imatinib trough level and response in CML patients: Long term follow-up, Leukemia Research, vol.34, issue.12, pp.1573-1578, 2010. ,
DOI : 10.1016/j.leukres.2010.07.014
First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm Reappraisal of histogenesis, ):26225. 11. Mazur MT, Clark HB. Gastric stromal tumors, pp.47507-47526, 1983. ,
Gastrointestinal stromal tumors: review on morphology, molecular pathology, diagnostics, prognosis and treatment options ,
The estimated incidence of gastrointestinal stromal tumors in France. Results of PROGIST study conducted among pathologists, Bull Cancer, vol.97, issue.3, pp.16-22, 2010. ,
A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumor, Gastroenterology, vol.114 ,
DOI : 10.1016/S0016-5085(98)82666-8
Tyrosine kinase inhibitor imatinib (STIS71) as an anticancer agent for solid tumours, Annals of Medicine, vol.20, issue.7, pp.451-456, 2001. ,
DOI : 10.1056/NEJM200104053441404
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial, The Lancet, vol.368, issue.9544, pp.1329-1367, 2006. ,
DOI : 10.1016/S0140-6736(06)69446-4
New approaches to molecular cancer therapeutics, Nature Chemical Biology, vol.2, issue.12, pp.689-700, 2006. ,
DOI : 10.1016/j.cbpa.2004.04.015
Methodological and practical challenges for personalized cancer therapies, Nature Reviews Clinical Oncology, vol.40, issue.3, pp.135-176, 2011. ,
DOI : 10.1053/j.semnuclmed.2010.05.002
EGFR Signaling and Drug Discovery, Oncology, vol.77, issue.6, pp.400-410, 2009. ,
DOI : 10.1159/000279388
Roles of EGFR and KRAS Mutations in the Treatment Of Patients With ,
Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer, Cancer Research, vol.66, issue.8, pp.3992-3997, 2006. ,
DOI : 10.1158/0008-5472.CAN-06-0191
BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: A review, Leukemia Research, vol.34, issue.10, pp.1255-68, 2010. ,
DOI : 10.1016/j.leukres.2010.04.016
Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia, Blood, vol.109, issue.8, pp.3496-3505, 2007. ,
DOI : 10.1182/blood-2006-07-036012
Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study, Blood, vol.111, issue.8, pp.4022-4030, 2008. ,
DOI : 10.1182/blood-2007-10-116475
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial, The Lancet Oncology, vol.11, issue.11, pp.1029-1064, 2010. ,
DOI : 10.1016/S1470-2045(10)70233-3
Absolute Bioavailability of Imatinib (Glivec??) Orally versus Intravenous Infusion, The Journal of Clinical Pharmacology, vol.24, issue.Suppl. 1, pp.158-62, 2004. ,
DOI : 10.1007/BF02353475
Clinical pharmacokinetics of tyrosine kinase inhibitors Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib, Population Br J Clin Pharmacol. Cancer Treat Rev. Blood, vol.6235117, issue.3288, pp.97-112692, 2006. ,
Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome, New England Journal of Medicine, vol.344, issue.14 ,
DOI : 10.1056/NEJM200104053441402
Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation, Blood, vol.99, issue.10, pp.3792-800, 2002. ,
DOI : 10.1182/blood.V99.10.3792
Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia, Leukemia, vol.114, issue.2, pp.201-211, 2011. ,
DOI : 10.1182/blood-2008-12-196543
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia, New England Journal of Medicine, vol.362, issue.24, pp.2260-70, 2010. ,
DOI : 10.1056/NEJMoa1002315
Metabolism and Disposition of Dasatinib after Oral Administration to Humans, Drug Metabolism and Disposition, vol.36, issue.7, pp.1357-64, 2008. ,
DOI : 10.1124/dmd.107.018267
Characterization of Dasatinib and Its Structural Analogs as CYP3A4 Mechanism-Based Inactivators and the Proposed Bioactivation Pathways, Drug Metabolism and Disposition, vol.37, issue.6, pp.1242-50, 2009. ,
DOI : 10.1124/dmd.108.025932
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia, New England Journal of Medicine, vol.362, issue.24, pp.2251-2260, 2010. ,
DOI : 10.1056/NEJMoa0912614
Pharmacokinetics and Pharmacodynamics of Nilotinib in Gastrointestinal Stromal Tumors, Seminars in Oncology, vol.38, issue.1, pp.28-33, 2011. ,
DOI : 10.1053/j.seminoncol.2011.01.014
Clinical Pharmacokinetics of the BCR???ABL Tyrosine Kinase Inhibitor Nilotinib, Clinical Pharmacology & Therapeutics, vol.106, issue.2, pp.197-203, 2009. ,
DOI : 10.5414/CPP38532
Nilotinib treatment-associated peripheral artery disease and sudden death: Yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia, American Journal of Hematology, vol.86, issue.7, pp.610-611, 2011. ,
DOI : 10.1002/ajh.22051
URL : http://onlinelibrary.wiley.com/doi/10.1002/ajh.22051/pdf
Correlation between trough imatinib plasma concentration and clinical response in chronic myeloid leukemia, Leukemia Research, vol.33, issue.8, pp.1147-1155, 2009. ,
DOI : 10.1016/j.leukres.2009.02.030
A Therapeutic Drug Monitoring Algorithm for Refining the Imatinib Trough Level Obtained at Different Sampling Times, Therapeutic Drug Monitoring, vol.31, issue.5, pp.579-84, 2009. ,
DOI : 10.1097/FTD.0b013e3181b2c8cf
Correlation Between Imatinib Pharmacokinetics and Clinical Response in Japanese Patients With Chronic-Phase Chronic Myeloid Leukemia, Clinical Pharmacology & Therapeutics, vol.49, issue.6, pp.809-822, 2010. ,
DOI : 10.1016/S1570-0232(01)00611-0
Imatinib plasma trough concentration and its correlation with characteristics and response in Chinese CML patients, Acta Pharmacologica Sinica, vol.46, issue.8 ,
DOI : 10.1007/s00277-008-0589-2
Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy, Blood, vol.117, issue.14, pp.3733-3739, 2011. ,
DOI : 10.1182/blood-2010-10-309807
Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group, Cancer Chemotherapy and Pharmacology, vol.364, issue.4, pp.379-86, 2005. ,
DOI : 10.1007/s00280-004-0876-0
Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing?, J Clin Oncol. Cancer Treat Rev, vol.2737, issue.4, pp.3141-7291, 2009. ,
Changes in imatinib plasma trough level during long-term treatment of patients with advanced gastrointestinal stromal tumors: correlation between changes in covariates and imatinib exposure Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability, Invest New Drugs. Br J Cancer, vol.98, issue.10, pp.1633-1673, 2008. ,
Imatinib assay by HPLC with photodiode-array UV detection in plasma from patients with chronic myeloid leukemia: Comparison with LC-MS/MS, Clinica Chimica Acta, vol.411, issue.3-4, pp.3-4140, 2010. ,
DOI : 10.1016/j.cca.2009.10.007
Quantification of the anti-leukemia drug STI571 (Gleevec???) and its metabolite (CGP 74588) in monkey plasma using a semi-automated solid phase extraction procedure and liquid chromatography-tandem mass spectrometry, Journal of Pharmaceutical and Biomedical Analysis, vol.28, issue.6, pp.1183-94, 2002. ,
DOI : 10.1016/S0731-7085(02)00080-8
Development and validation of a simple liquid chromatographic method with ultraviolet detection for the determination of imatinib in biological samples, Journal of Chromatography B, vol.804, issue.2, pp.431-435, 2004. ,
DOI : 10.1016/j.jchromb.2004.01.032
Reversed-phase liquid chromatography analysis of imatinib mesylate and impurity product in Glivec?? capsules, Journal of Chromatography B, vol.800, issue.1-2 ,
DOI : 10.1016/j.jchromb.2003.10.018
Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells, Leukemia, vol.25, issue.6, pp.985-94, 2011. ,
DOI : 10.1182/blood-2008-06-164582
Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I, Cancer, vol.26, issue.15S, pp.3631-3638, 2010. ,
DOI : 10.1002/cncr.25092
Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC, OncoTargets and Therapy, vol.4, pp.43-58, 2011. ,
DOI : 10.2147/OTT.S18155
A simple HPLC-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasma, Journal of Chromatography B, vol.879, issue.23, pp.2345-50, 2011. ,
DOI : 10.1016/j.jchromb.2011.06.026
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer, New England Journal of Medicine, vol.355, issue.26, pp.2733-2776, 2006. ,
DOI : 10.1056/NEJMoa064320
Determination of lapatinib (GW572016) in human plasma by liquid chromatography electrospray tandem mass spectrometry (LC???ESI-MS/MS), Journal of Chromatography B, vol.831, issue.1-2, pp.169-75, 2006. ,
DOI : 10.1016/j.jchromb.2005.11.044
Development of a high-performance liquid chromatographic???mass spectrometric method for the determination of cellular levels of the tyrosine kinase inhibitors lapatinib and dasatinib, Journal of Chromatography B, vol.877, issue.31, pp.3982-90, 2009. ,
DOI : 10.1016/j.jchromb.2009.10.008